Antares Pharma Sees Significant Increase in Short Interest (ATRS)
Shares of Antares Pharma (NASDAQ:ATRS) were the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 17,467,069 shares, a growth of 10.5% from the April 15th total of 15,809,635 shares, StockRatingsNetwork.com reports. Currently, 15.0% of the company’s shares are short sold. Based on an average daily volume of 1,317,756 shares, the days-to-cover ratio is presently 13.3 days.
ATRS has been the subject of a number of recent research reports. Analysts at Oppenheimer cut their price target on shares of Antares Pharma from $6.00 to $5.00 in a research note on Friday, May 9th. They now have an “outperform” rating on the stock. Separately, analysts at Ladenburg Thalmann cut their price target on shares of Antares Pharma from $6.50 to $6.00 in a research note on Monday, May 5th. Finally, analysts at TheStreet downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, April 7th.
Antares Pharma (NASDAQ:ATRS) opened at 2.94 on Thursday. Antares Pharma has a one year low of $2.43 and a one year high of $5.15. The stock has a 50-day moving average of $3.1 and a 200-day moving average of $3.96. The company’s market cap is $381.2 million.
Antares Pharma (NASDAQ:ATRS) last released its earnings data on Friday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.02. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million. Analysts expect that Antares Pharma will post $-0.21 EPS for the current fiscal year.
Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.